Loading...
•
Sep 30, 2021
Amneal Q3 2021 Earnings Report
Amneal's Q3 2021 financial performance reflected growth and value creation strategy, driven by operational excellence and innovation, with net revenue at $529 million and adjusted diluted EPS at $0.21.
Key Takeaways
Amneal reported a solid third quarter with net revenue of $529 million, a net loss of $4 million, and adjusted diluted EPS of $0.21. The company is updating its full year financial outlook, including raising adjusted EBITDA and adjusted EPS guidance. They also announced the acquisition of Puniska Healthcare.
Net revenue in Q3 2021 was $529 million, an increase of 2% compared to Q3 2020.
Net loss attributable to Amneal Pharmaceuticals, Inc. was $4 million in Q3 2021, compared to a net loss of $9 million in Q3 2020.
Adjusted EBITDA in Q3 2021 was $135 million, an increase of 19% compared to Q3 2020.
Adjusted diluted EPS in Q3 2021 was $0.21, an increase of 31% from $0.16 in Q3 2020.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Specialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal is updating its previously provided guidance for the full year 2021.
Positive Outlook
- Net revenue is expected to be approximately $2.1 billion.
- Adjusted EBITDA is expected to be between $530 million and $550 million.
- Adjusted diluted EPS is expected to be between $0.78 and $0.88.
- Operating cash flow is expected to be between $220 million and $250 million.
- Capital expenditures are expected to be between $50 million and $60 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income